Ultromics

#ASE2026 is just one month away, and Ultromics is excited to attend! We look forward to connecting and sharing how EchoGo®, powered by AI, is being implemented in echocardiography workflows to support detection of complex cardiac diseases, including HFpEF and cardiac amyloidosis. #HeartFailure #CardiacInnovation #MedTech

Built for clinical practice. Backed by evidence. Ultromics’ EchoGo® platform supports early disease detection across HFpEF and cardiac amyloidosis, backed by strong peer-reviewed research. Designed to integrate seamlessly into existing echocardiography workflows, EchoGo® delivers AI-driven insights in minutes to augment clinical decision-making and support the appropriate care pathway. Learn more about how Ultromics' AI can impact your practice at hubs.la/Q04hGy110 #HeartFailure #ClinicalAI #HFpEF #Amyloidosis #ATTRCM

Ultromics’ AI supports early disease detection with strong peer-reviewed validation across HFpEF and cardiac amyloidosis. HFpEF → 90% sensitivity | 86% specificity Cardiac amyloidosis → 85% sensitivity | 93% specificity Learn more at ultromics.com/resources/the-… #CardioTwitter #ClinicalInnovation #ATTRCM #Amyloid #HFpEF #Cardiology

Research suggests that around 2/3 of cases may be missed using standard diagnostic approaches, despite the increased risk of heart failure hospitalization and mortality associated with delayed recognition. As the burden of complex cardiac disease continues to grow, there remains a need for tools that support early clinical consideration. Learn how EchoGo® integrates into existing echo workflows to support detection of HFpEF and cardiac amyloidosis from routine echocardiograms. 🔗hubs.la/Q04h9KrK0 #HeartFailure #HFpEF #CardiacAmyloidosis #Echocardiography #AIinHealthcare

Peer-reviewed research published in the European Heart Journal demonstrates that EchoGo® Amyloidosis outperforms traditional clinical scores, including TCAS and IWT, while maintaining consistent performance across amyloidosis subgroups. With strong diagnostic performance (85% sensitivity, 93% specificity) and low risk of bias, EchoGo® Amyloidosis supports early clinical consideration to help address persistent diagnostic delays. 🔗hubs.la/Q04gHrt00 #ATTRCM #CardiacAmyloidosis #CardiacSonography #HealthcareAI

Earlier identification is associated with reduced mortality and fewer heart failure hospitalizations, highlighting the importance of timely detection. EchoGo® Amyloidosis supports identification from routine echocardiography, helping clinicians detect signs of disease before symptoms are overlooked or dismissed. Learn more at ultromics.com Spencer-Bonilla G et al., JAMA Cardiol. 2026.

Physician perspectives continue to shape the conversation around AI in cardiology. The Verse highlights clinician voices, real-world implementation stories, and conversations around the role EchoGo® can play in supporting the detection of complex diseases like HFpEF and Cardiac Amyloidosis. Learn more at ultromics.com/the-verse #Echocardiography #Cardiology #AIinHealthcare #HFpEF #CardiacAmyloidosis

🔍Curious how EchoGo® can fit into your echocardiography workflow? The Verse highlights how EchoGo® is being implemented in practice—showcasing operational utility, clinical credibility, and real-world impact. From expert perspectives to real-world implementation stories, explore how Ultromics' AI is being applied to routine echocardiography. Visit hubs.la/Q04fyt7y0 to learn more! #Echocardiography #Cardiology #AIinHealthcare #HFpEF #ATTRCM

Clinical complexity can make timely detection more challenging. Ultromics’ clinically validated AI integrates into existing cardiology workflows to support detection and help guide timely next steps in care. Learn more about how EchoGo® Heart Failure and EchoGo® Amyloidosis can impact your practice, visit hubs.ly/Q04f9D4V0 #AIinHealthcare #HFpEF #ATTRCM #HealthTech

Clinical presentation can vary significantly across patient populations—making rigorous validation essential for AI tools designed to support cardiovascular care. EchoGo® is built on a foundation of robust clinical evidence, with performance validated through extensive research and peer-reviewed publications. Explore the clinical evidence: ultromics.com/hubfs/Ultromic… #AIinHealthcare #ClinicalComplexities #HFpEF #ATTRCM

HFpEF and cardiac amyloidosis often present with nonspecific symptoms, comorbidities, and subtle cardiac findings—factors that can complicate recognition in standard clinical practice. Ultromics' clinically validated AI is applied to routine echocardiography to support early detection and augment clinical evaluation for complex cardiac diseases. #HFpEF #ATTRCM #HeartFailure #DigitalHealth #AIinHealthcare

EchoGo® is validated across 25+ peer-reviewed publications and is in use across leading U.S. hospitals. Designed to integrate into existing echocardiography workflows, EchoGo® Heart Failure and EchoGo® Amyloidosis deliver AI-supported insights—without disrupting clinical practice. Explore the clinical evidence: hubs.la/Q04dgcpr0 #AIinHealthcare #MedTech #DigitalHealth #HFpEF #ATTRCM

🫀 We detect from a single apical 4-chamber (A4C) view. 🩺 You interpret, confirm, and guide the next steps in care. EchoGo® applies clinically validated AI to routine echocardiography, helping surface patterns associated with HFpEF and Cardiac Amyloidosis and supporting clinical evaluation without disrupting reading workflows. We detect. You diagnose. #Echocardiography #AIinHealthcare #HFpEF #ATTRCM #DigitalHealth

Members of our team will be on site in California for Innovation in Cardiovascular Care: Digital Intelligence & Therapeutic Breakthroughs. We look forward to connecting with attendees and sharing how Ultromics’ clinically validated AI supports detection of HFpEF and Cardiac Amyloidosis. #DigitalHealth #AIinHealthcare #HFpEF #ATTRCM #Echocardiology

📢 Can patients trust AI in the presence of comorbidities—across age and gender—especially when care spans multiple specialties? Dr. Patricia Pellikka, MD shares her perspective. EchoGo® models are grounded in scientific rigor and validated across 25+ peer-reviewed publications. Explore the clinical evidence: hubs.la/Q04cwZ3z0 #Cardiology #AIinHealthcare #Echocardiography #ClinicalAI #DigitalHealth

HFpEF doesn’t always present the same way, especially in women. Variability in presentation and symptom overlap can make identification more challenging. Dr. @carinehamo shares key insights in the clip here: hubs.la/Q04bZLZC0 #HFpEF #HeartFailure #Echocardiography #WomensHealth #AIinHealthcare

From a single apical four-chamber (A4C) view to AI-driven insights. Ultromics’ EchoGo® platform analyzes a routine A4C clip to support detection of HFpEF and Cardiac Amyloidosis—integrating seamlessly into existing echocardiography workflows. EchoGo® returns results in under 20 minutes to augment clinical decision-making and help guide patients along the appropriate care pathway. Want to learn more? Schedule a demo using the link below. 🔗 hubs.la/Q04bsGhP0 #AiInsights #ClinicalInnovation #HFpEF #ATTRCM

What are the most compelling clinical justifications for implementing an AI platform in a health system? 📢 Dr. @pattypellikka shares key considerations for health systems evaluating AI integration—and where it can deliver meaningful clinical value. #ClinicalInnovation #HFpEF #ATTRCM #AIinHealthcare

In our Febrary webinar, we explored gender disparities in heart failure and the role AI may play in reducing bias and supporting early detection. Moderator and speaker Dr. Sangita Sudharshan opened the discussion by sharing key insights on heart failure and its impact on women. Hear more in the clip below. 🎥 hubs.la/Q049Y9tk0 #ClinicalInnovation #HFpEF #HeartFailure #AiInsights

ASE experts connect with industry partners to drive advances in the field like #Strain #3DEcho & #ArtificialIntelligence while focusing on disease diagnosis in #HCM #Amyloidosis #ValveDisease & more! bit.ly/4247EQ4 #ASEIRT #PartnersInInnovation #HeartofASE #ASEMemberDay